中国HPV疫苗纳入国家免疫规划:生命全程免疫的进程、意义与前景
本文评述此举对宫颈癌消除及生命全程疫苗接种的意义,指出私营市场接种覆盖率低、不公平且偏离目标人群,而纳入国家规划可确保在性行为开始前公平接种。文章还讨论了本地疾病负担证据、充足可负担的国产疫苗及五年大规模试点对全国推广的价值。
要点
- 私营市场时代HPV疫苗覆盖率低、不公平且偏离目标人群。
- 纳入规划确保在性行为开始前公平获得疫苗接种。
核心结论
- HPV疫苗纳入国家免疫规划可确保公平接种并把握性行为开始前的适龄时机,助力宫颈癌消除。
- 政府背书政策有助于增强公众信任、 counter vaccine hesitancy。
- 中国疫苗研发生态强化及参与WHO预认证促进全球可负担疫苗供应。
研究设计与样本
- 本文为评论性文章(commentary),非原始研究。
- 讨论中国HPV疫苗纳入国家免疫规划的意义及生命全程疫苗接种前景。
主要发现
- 私营市场HPV疫苗供应十年间导致覆盖率低、不公平且偏离目标人群。
- 五年大规模试点引入给予政府全国推广信心。
关键数值与推荐
- 国家免疫规划目标人群为13岁女孩。
- 私营市场HPV疫苗覆盖表现为低、不公平和偏离目标。
临床怎么用
- 公共卫生医生应把握13岁女孩接种窗口,在性行为开始前完成HPV疫苗接种。
- 利用政府背书政策应对疫苗犹豫,强化公众信任。
局限性
- 原文为评论性文章,未报告原始研究数据或系统评价方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
China recently announced inclusion of HPV vaccine into the National Immunization Program for 13-year-old females, directly benefiting annual cohorts of 7-8 million girls. This commentary discusses the significance of HPV vaccine introduction in China and the prospects for life-course vaccination and global collaboration for cervical cancer elimination. Private-sector HPV vaccine availability over the past decade yielded low, inequitable, and off-target coverage, while program inclusion ensures equitable access, properly timed before sexual debut. We describe necessities of locally-obtained burden-of-disease evidence and ample, affordable domestic HPV vaccine, and show the value of five years of large-scale pilot introductions that gave government confidence in nationwide introduction. Government-backed policy counters vaccine hesitancy by reinforcing public trust, and China's strengthening vaccine R&D ecosystem and participation in WHO prequalification promote affordable global vaccine supply. HPV inclusion aligns with Immunization Agenda 2030 priorities on coverage, equity, life-course vaccination, and sustainable supply.
引用
- Zundong Y, Xiaoxue L, Rodewald L, et al. Entering into life-course immunization: Process, significance, and prospects of HPV vaccine inclusion into the national immunization program of China. Vaccine. 2026. PMID: 42551399. doi:10.1016/j.vaccine.2026.129000
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。